CLL Support Association
9,291 members14,668 posts

Encouraging results from son of Ibrutinib studies (Acalabrutinib/Calquence)

In case you need any more persuasion that we are in exiting times for the future of CLL, read this article about the exciting results of a drug which all being well may one day replace ibrutinib. Not every promising drug gets all the way through. But when you have a drug with a similar target but hopefully fewer side effects the likelihood of success improves.

cancer.osu.edu/news-and-med...

Title changed so information on Acalabrutinib/Calquence can be found via Search - Admin

17 Replies
oldestnewest

It’s already approved for Mantle cell cancer. I’m hoping we’re next this year.

I’m guessing if you’re intolerant to Ibrutinib it will be the go to drug.

4 likes
Reply

Do you know the name of the drug?

Reply

Calquence (acalabrutinib) should be available in the U.S. fall 2018, but no sure bets.

~chris

7 likes
Reply

For CLL?

Reply

while not officially approved for CLL by the FDA, it is being prescribed by many docs for patients with R/R CLL who are having problems with ibrutinib. And some insurance companies are approving the Rx for CLL, too.

1 like
Reply

Why isn't it available now Chris?

Reply

Its up to the drug company to start the process for approval, likely they are waiting for more data. Since its already been reviewed by the FDA for safety concerns in the MCL approval, it's easier and faster to get a second indication, CLL second line approved.

I don't know were things stand at the moment, Astrazeneca hasn't given any indications either...

~chris

1 like
Reply

Ibrutinib works well for me so far, but love having another drug on the shelf just in case. Thanks, Sally

2 likes
Reply

Good news obviously, less side effects such as AF..

BUT will it be affordable, and can NICE agree a price in the UK that the NHS will also agree to.???

Dick

2 likes
Reply

Pricing should be in line with Ibrutinib.

Reply

Second in class drugs have a rough time, some like ofatumumab fail...simply due to cost. I hope Calquence (acalabrutinib) comes to market at about $90,000 annually, compared to Imbruvica (ibrutinib) at $148,000 it will be a bargain.. win over funders and insurance companies, get it in broad use, then worry about price.

~chris

6 likes
Reply

Getting the pricing strategy right will be crucial for them. What’s the price for their current indication?

Reply

100mg BID, for MCL

The wholesale acquisition cost for Calquence is $14,260 per month, certainly comparable to Imbruvica (ibrutinib), but who knows...

I have no idea of the market size... drug pricing in the U.S. is largely smoke and mirrors.

professionals.optumrx.com/c...

Also see

reference.medscape.com/drug...

~chris

3 likes
Reply

I hope so. I can't take Ibrutinib due to mild cardiac issues so my choices are Bendamustine with Rituxan or Gazyva. Sadly, I think Ibrutinib would work for me😕

3 likes
Reply

Hang in there. It will come.

Reply

You did it again, AdianUK! Thanks for sending this link.

Our CLL treatments keep improving to give us a brighter future.

Wishing good days and good health to all.

SMS

Reply

I have been on acalabrutinib for 18 months very successfully with few side effects. Truly has been a blessing.

6 likes
Reply

You may also like...